Regulation of stem-like CD8+ T cells and their role in immunotherapy
干细胞样 CD8 T 细胞的调节及其在免疫治疗中的作用
基本信息
- 批准号:10400137
- 负责人:
- 金额:$ 40.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-03-01 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAntigen-Presenting CellsAntitumor ResponseBiologyCD8-Positive T-LymphocytesCD8B1 geneCTLA4 geneCancer PatientCell CommunicationCell physiologyCellsClinicalCommunicationDataDendritic CellsExhibitsGenerationsGenesGenomicsGoalsHumanImmuneImmunotherapyInflammatoryKnockout MiceKnowledgeLicensingMaintenanceMalignant NeoplasmsMalignant neoplasm of lungMediator of activation proteinMemoryModificationMorbidity - disease rateMusOutcomePatientsPhenotypePlayPopulationPositioning AttributeProductionRNARegulationRenal carcinomaReporterReportingRoleSamplingT cell responseT-LymphocyteTCF Transcription FactorTechnologyTestingTumor AntigensTumor TissueTumor-Infiltrating Lymphocytescancer therapycancer typecheckpoint receptorscytokinecytotoxicityexhaustgenome editingimmune checkpointimmune checkpoint blockadeimprovedintercellular communicationloss of functionmelanomamortalityneoplastic cellnovelprogrammed cell death protein 1receptor expressionresponsestemstem cellssuccesstooltranscriptomicstreatment responsetumortumor microenvironment
项目摘要
PROJECT SUMMARY
Immune checkpoint receptors (e.g. CTLA-4, PD-1, Tim-3) are expressed on dysfunctional or “exhausted” CD8+
tumor-infiltrating lymphocytes (TILs) that exhibit defective effector functions (cytotoxicity and pro-inflammatory
cytokine production) and are thus poor mediators of tumor clearance. In the last decade, immune checkpoint
blockade (ICB) has achieved durable responses in many cancers, including melanoma, lung, and renal cancer.
Despite this success, current estimates indicate that only 12% of all cancer patients respond to ICB. These
observations underscore the remaining unmet clinical need in cancer treatment and the need to understand what
constitutes effective response to ICB in order to improve response rates.
Through examination of the population and single-cell RNA profiles of CD8+ TILs upon ICB, we have identified
stem-like CD8+ TILs that are integral for the response to ICB. These cells are tumor antigen-specific, exhibit
polyfunctional effector capacity, and increase in proportion upon various ICBs across different cancer types.
Although the transcription factor TCF-1 plays an important role in the maintenance and effector function of these
cells, we have found that TCF-1 expression in CD8+ T cells is not requisite for positive response to ICB in all
tumor contexts. These observations underscore the relevance of stem-like CD8+ TILs for effective response to
ICB and the need to better understand how TCF-1 and additional factors regulate their biology.
Stem cells reside in niches where crosstalk between stem cells and other cells in the niche regulates not only
their maintenance and function but also the function of niche cells. We have found that tumor-associated dendritic
cells (DCs) are altered when TCF-1 is absent in mature CD8+ T cells. We thus hypothesize that 1) stem-like
CD8+ TILs reside within niches in the tumor micro-environment (TME) where they interact with and modulate
antigen-presenting cells; 2) this intercellular communication circuit within the niche may be required for effective
priming of anti-tumor T cell responses; and 3) modulation of stem-like CD8+ TILs may positively or negatively
influence this communication circuit, thus affecting the efficacy of ICB.
Our overarching goal is to understand the cell-autonomous regulation of stem-like CD8+ TILs, their
crosstalk with other cells in the TME, and how together they govern the activation of proficient anti-
tumor CD8+ T cell responses and ICB efficacy. Accordingly, we propose the following aims: 1) Determine the
role of TCF-1 in the generation of proficient anti-tumor T cell responses; 2) Test the role of novel candidate
regulators of stem- and effector-like CD8+ TILs, and 3) Characterize the crosstalk between stem-like CD8+ TILs
and the TME.
项目概要
免疫检查点受体(例如 CTLA-4、PD-1、Tim-3)在功能失调或“耗尽”的 CD8+ 上表达
表现出有缺陷的效应功能(细胞毒性和促炎性)的肿瘤浸润淋巴细胞(TIL)
细胞因子的产生),因此是肿瘤清除的不良介质。近十年来,免疫检查点
阻断(ICB)已在许多癌症中取得了持久的缓解,包括黑色素瘤、肺癌和肾癌。
尽管取得了这一成功,但目前的估计表明,只有 12% 的癌症患者对 ICB 有反应。这些
观察强调了癌症治疗中剩余的未满足的临床需求以及需要了解什么
构成对 ICB 的有效应对,以提高应对率。
通过检查 ICB 上 CD8+ TIL 的群体和单细胞 RNA 谱,我们发现
干状 CD8+ TIL 是对 ICB 反应不可或缺的一部分。这些细胞具有肿瘤抗原特异性,表现出
多功能效应器能力,并且在不同癌症类型的各种 ICB 上按比例增加。
尽管转录因子TCF-1在这些细胞的维持和效应功能中发挥着重要作用。
细胞中,我们发现 CD8+ T 细胞中的 TCF-1 表达并不是所有 ICB 阳性反应所必需的。
肿瘤背景。这些观察结果强调了干细胞样 CD8+ TIL 与有效应对
ICB 以及更好地了解 TCF-1 和其他因子如何调节其生物学的需要。
干细胞驻留在微环境中,干细胞与微环境中其他细胞之间的串扰不仅调节
它们的维护和功能以及生态位细胞的功能。我们发现肿瘤相关的树突状
当成熟 CD8+ T 细胞中缺乏 TCF-1 时,DC 细胞 (DC) 就会发生改变。因此我们假设 1) 茎状
CD8+ TIL 存在于肿瘤微环境 (TME) 的微环境中,它们在其中相互作用并进行调节
抗原呈递细胞; 2) 生态位内的细胞间通讯电路可能需要有效的
启动抗肿瘤 T 细胞反应; 3) 干样 CD8+ TIL 的调节可能是正向或负向的
影响这个通讯电路,从而影响ICB的功效。
我们的首要目标是了解干细胞样 CD8+ TIL 的细胞自主调节、它们的
与 TME 中其他细胞的串扰,以及它们如何共同控制有效抗-细胞因子的激活
肿瘤 CD8+ T 细胞反应和 ICB 功效。因此,我们提出以下目标: 1) 确定
TCF-1 在产生高效抗肿瘤 T 细胞反应中的作用; 2)测试新候选人的角色
干细胞和效应子样 CD8+ TIL 的调节因子,以及 3) 表征干细胞样 CD8+ TIL 之间的串扰
和 TME。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(4)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANA C ANDERSON其他文献
ANA C ANDERSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANA C ANDERSON', 18)}}的其他基金
A TCF1:Glucocorticoid regulatory circuit controls IL-23-driven Th17 pathogenicity
TCF1:糖皮质激素调节电路控制 IL-23 驱动的 Th17 致病性
- 批准号:
10635984 - 财政年份:2023
- 资助金额:
$ 40.34万 - 项目类别:
Role of metabolic crosstalk in determining immunity during tumor progression
代谢串扰在肿瘤进展过程中决定免疫的作用
- 批准号:
10718070 - 财政年份:2023
- 资助金额:
$ 40.34万 - 项目类别:
Steroid hormone regulation of immune responses
类固醇激素对免疫反应的调节
- 批准号:
10189531 - 财政年份:2018
- 资助金额:
$ 40.34万 - 项目类别:
Steroid hormone regulation of immune responses
类固醇激素对免疫反应的调节
- 批准号:
10418699 - 财政年份:2018
- 资助金额:
$ 40.34万 - 项目类别:
Role of Tim-3 in determining T cell immunity
Tim-3 在决定 T 细胞免疫中的作用
- 批准号:
9024492 - 财政年份:2015
- 资助金额:
$ 40.34万 - 项目类别:
Role of Tim-3 in determining T cell immunity
Tim-3 在决定 T 细胞免疫中的作用
- 批准号:
9210064 - 财政年份:2015
- 资助金额:
$ 40.34万 - 项目类别:
Regulation of stem-like CD8+ T cells and their role in immunotherapy
干细胞样 CD8 T 细胞的调节及其在免疫治疗中的作用
- 批准号:
10211084 - 财政年份:2015
- 资助金额:
$ 40.34万 - 项目类别:
Regulation of stem-like CD8+ T cells and their role in immunotherapy
干细胞样 CD8 T 细胞的调节及其在免疫治疗中的作用
- 批准号:
10622463 - 财政年份:2015
- 资助金额:
$ 40.34万 - 项目类别:
Genetic Elements that Influence Susceptibility to CNS Autoimmunity
影响中枢神经系统自身免疫易感性的遗传因素
- 批准号:
7371005 - 财政年份:2006
- 资助金额:
$ 40.34万 - 项目类别:
Genetic Elements that Influence Susceptibility to CNS Autoimmunity
影响中枢神经系统自身免疫易感性的遗传因素
- 批准号:
7176038 - 财政年份:2006
- 资助金额:
$ 40.34万 - 项目类别:
相似海外基金
Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
- 批准号:
10751133 - 财政年份:2023
- 资助金额:
$ 40.34万 - 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
- 批准号:
10696138 - 财政年份:2022
- 资助金额:
$ 40.34万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10663066 - 财政年份:2022
- 资助金额:
$ 40.34万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10537159 - 财政年份:2022
- 资助金额:
$ 40.34万 - 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
- 批准号:
21K08723 - 财政年份:2021
- 资助金额:
$ 40.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10156950 - 财政年份:2021
- 资助金额:
$ 40.34万 - 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
- 批准号:
10631854 - 财政年份:2021
- 资助金额:
$ 40.34万 - 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
- 批准号:
10153927 - 财政年份:2021
- 资助金额:
$ 40.34万 - 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10331830 - 财政年份:2021
- 资助金额:
$ 40.34万 - 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
- 批准号:
20K16294 - 财政年份:2020
- 资助金额:
$ 40.34万 - 项目类别:
Grant-in-Aid for Early-Career Scientists